

Camille Nelson Kotton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1110456/publications.pdf>

Version: 2024-02-01

83
papers

4,569
citations

236833

25
h-index

102432

66
g-index

86
all docs

86
docs citations

86
times ranked

5243
citing authors

#	ARTICLE	IF	CITATIONS
1	International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. <i>Transplantation</i> , 2010, 89, 779-795.	0.5	898
2	The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. <i>Transplantation</i> , 2018, 102, 900-931.	0.5	784
3	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 96, 333-360.	0.5	651
4	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4090-e4099.	2.9	332
5	Viral Infection in the Renal Transplant Recipient. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1758-1774.	3.0	191
6	Zoonoses in Solid-Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2007, 44, 857-866.	2.9	141
7	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 68, 1420-1426.	2.9	136
8	Enteric Pathogens as Vaccine Vectors for Foreign Antigen Delivery. <i>Infection and Immunity</i> , 2004, 72, 5535-5547.	1.0	105
9	Management of cytomegalovirus infection in solid organ transplantation. <i>Nature Reviews Nephrology</i> , 2010, 6, 711-721.	4.1	102
10	A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2505-2516.	2.6	84
11	Prevention of Infection in Adult Travelers After Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 8-14.	2.6	75
12	The Status of Vaccine Development Against the Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 221, S113-S122.	1.9	73
13	Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 771-780.	3.7	66
14	Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. <i>American Journal of Transplantation</i> , 2022, 22, 279-288.	2.6	63
15	Safety and immunogenicity of attenuated <i>Salmonella enterica</i> serovar Typhimurium delivering an HIV-1 Gag antigen via the <i>Salmonella</i> Type III secretion system. <i>Vaccine</i> , 2006, 24, 6216-6224.	1.7	54
16	Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, 193-208.	0.5	53
17	Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, S1-S7.	0.5	41
18	Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1282-1286.	2.6	40

#	ARTICLE	IF	CITATIONS
19	Travel medicine, transplant tourism, and the solid organ transplant recipientâ€™ Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13529.	0.8	39
20	COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. <i>American Journal of Transplantation</i> , 2021, 21, 2774-2784.	2.6	37
21	Letemovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13687.	0.7	34
22	Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients. <i>Surgical Infections</i> , 2017, 18, 128-136.	0.7	32
23	Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. <i>American Journal of Transplantation</i> , 2020, 20, 1619-1628.	2.6	31
24	Updates on antiviral drugs for cytomegalovirus prevention and treatment. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 469-475.	0.8	30
25	Vaccination and immunization against travel-related diseases in immunocompromised hosts. <i>Expert Review of Vaccines</i> , 2008, 7, 663-672.	2.0	27
26	Marijuana use in transplantation: A call for clarity. <i>Clinical Transplantation</i> , 2019, 33, e13456.	0.8	26
27	Vaccines and Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2010, 28, 525-535.	0.8	24
28	Travel and transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, 17, 594-600.	0.8	23
29	Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety. <i>Transplant Infectious Disease</i> , 2017, 19, e12791.	0.7	20
30	Immunization after kidney transplantationâ€™ what is necessary and what is safe?. <i>Nature Reviews Nephrology</i> , 2014, 10, 555-562.	4.1	18
31	Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late <sc>CMV</sc> disease. <i>Transplant Infectious Disease</i> , 2018, 20, e12929.	0.7	18
32	Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 838985.	2.2	16
33	Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. <i>Clinical Microbiology and Infection</i> , 2023, 29, 44-50.	2.8	16
34	Nailing down the shingles in IBD. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1178-1179.	0.9	15
35	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. <i>Blood Advances</i> , 2022, , .	2.5	14
36	What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14631.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients. <i>Annals of Internal Medicine</i> , 2022, 175, 892-894.	2.0	13
38	Use of organs from donors with bloodstream infection, pneumonia, and influenza: Results of a survey of infectious diseases practitioners. <i>Transplant Infectious Disease</i> , 2017, 19, e12645.	0.7	12
39	Emerging Microbiology Diagnostics for Transplant Infections: On the Cusp of a Paradigm Shift. <i>Transplantation</i> , 2020, 104, 1358-1384.	0.5	12
40	Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2020, 52, 2654-2658.	0.3	11
41	Chagas disease reactivation in a heart transplant patient infected by domestic <i>Trypanosoma cruzi</i> discrete typing unit I (TcIDOM). <i>Parasites and Vectors</i> , 2015, 8, 435.	1.0	10
42	Zika Virus and Solid Organ Transplantation. <i>Transplantation</i> , 2016, 100, 970-972.	0.5	10
43	Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastrostomy tube: A case report. <i>Transplant Infectious Disease</i> , 2019, 21, e13048.	0.7	10
44	Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus. <i>Therapeutics and Clinical Risk Management</i> , 2022, Volume 18, 223-232.	0.9	10
45	Update on infectious diseases in pediatric solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 500-505.	0.8	9
46	Liver Transplantation for Recurrent Cholangitis From Von Meyenburg Complexes. <i>Transplantation Direct</i> , 2019, 5, e428.	0.8	9
47	Immunizations in Chronic Kidney Disease and Kidney Transplantation. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 47-65.	0.8	9
48	Case 15-2009. <i>New England Journal of Medicine</i> , 2009, 360, 2118-2125.	13.9	8
49	Vaccination of Oncology Patients: An Effective Tool and an Opportunity Not to Be Missed. <i>Oncologist</i> , 2012, 17, 1-2.	1.9	8
50	Coronavirus Disease 2019 (COVID-19) Diagnostic Clinical Decision Support: A Pre-Post Implementation Study of CORAL (COvid Risk cALculator). <i>Clinical Infectious Diseases</i> , 2021, 73, 2248-2256.	2.9	8
51	Skin and soft tissue infections in the transplant population. <i>Current Infectious Disease Reports</i> , 2008, 10, 387-393.	1.3	7
52	A Neurologist's Guide to Safe Use of Immunomodulatory Therapies. <i>Seminars in Neurology</i> , 2014, 34, 467-478.	0.5	7
53	Torque Teno Virus: Predictor of Infection After Solid Organ Transplant?. <i>Journal of Infectious Diseases</i> , 2018, 218, 1185-1187.	1.9	7
54	Successful Living Kidney Donation After COVID-19 Infection. <i>Transplantation</i> , 2021, 105, e4-e5.	0.5	7

#	ARTICLE	IF	CITATIONS
55	Post kidney transplant histoplasmosis: An under-recognized diagnosis in India. <i>Transplant Infectious Disease</i> , 2020, 23, e13523.	0.7	6
56	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718.	2.9	6
57	Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. <i>American Journal of Transplantation</i> , 2022, 22, 986-990.	2.6	6
58	Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of Driveline Infections in Patients With Continuous-Flow Left Ventricular Assist Devices. <i>Artificial Organs</i> , 2017, 41, 169-175.	1.0	5
59	Migrating From Universal to Personalized Prevention: Predicting the Risk of Cytomegalovirus Infection After Organ Transplantation. <i>Transplantation</i> , 2018, 102, 1787-1788.	0.5	5
60	Voriconazole-Induced Periostitis & Entesopathy in Solid Organ Transplant Patients: Case Reports. <i>Journal of Biosciences and Medicines</i> , 2016, 04, 8-17.	0.1	5
61	Training in transplant infectious diseases: A survey of infectious diseases and transplant infectious diseases fellows in the United States and Canada. <i>Transplant Infectious Disease</i> , 2018, 20, e12915.	0.7	4
62	Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13531.	0.7	4
63	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2021, 105, 2632-2638.	0.5	4
64	Optimizing the immunogenicity of pandemic H1N1 2009 influenza vaccine in adult organ transplant patients. <i>Expert Review of Vaccines</i> , 2012, 11, 423-426.	2.0	3
65	Preventative Tools of the Future. <i>Transplantation</i> , 2012, 93, 467-468.	0.5	3
66	Transplant center support for infectious diseases. <i>Transplant Infectious Disease</i> , 2017, 19, e12746.	0.7	3
67	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
68	Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19. <i>Clinical Transplantation</i> , 2021, 35, e14174.	0.8	3
69	Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 1343-1347.	0.8	2
70	Evaluation of low dose famciclovir as herpes simplex virus and varicella zoster virus prophylaxis in cytomegalovirus low-risk solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13711.	0.7	2
71	A call for caution in the immunocompromised: COVID-19 associated with mortality in a vaccinated lung transplant recipient. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab557.	0.4	2
72	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. <i>Clinical Transplantation</i> , 2022, 36, e14660.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Cytomegalovirus immunodiagnostics: Getting closer to personalized cytomegalovirus prevention?. Liver Transplantation, 2015, 21, 1462-1464.	1.3	1
74	1531. A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 Is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S475-S475.	0.4	1
75	A Fine Balance: Using Letermovir for Salvage Antiviral Treatment While Preserving Efficacy. Transplantation, 2020, 104, 240-241.	0.5	1
76	Risk of Serotonin Syndrome with Isoniazid. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	1
77	Infectious disease complications of transplant tourism. Expert Review of Anti-Infective Therapy, 2021, 19, 671-673.	2.0	1
78	Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report. Transplant Infectious Disease, 2021, 23, e13575.	0.7	1
79	Successful use of azithromycin for Escherichia coli-associated renal allograft malakoplakia: a report of two cases. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2627-2631.	1.3	1
80	Taming the Beast. Transplantation, 2015, 99, 2020-2021.	0.5	0
81	Travel and Transplantation. , 2019, , 1081-1094.		0
82	Preemptive Therapy vs Antiviral Prophylaxis in Cytomegalovirus-Seronegative Liver Transplant Recipients With Seropositive Donors. JAMA - Journal of the American Medical Association, 2020, 324, 1107.	3.8	0
83	Heterogeneity in transplant center responses to the minimum acceptance criteria across UNOS regions. Clinical Transplantation, 2021, , e14551.	0.8	0